Abstract
The long-term outlook for most patients with esophageal carcinoma remains poor, but surgery continues to provide excellent palliation and the best chance for cure. Careful preoperative staging and patient selection, combined with a well-performed operation, lead to low surgical morbidity and mortality with good functional results. The long-term survival of these patients continues to be determined by the advanced state of most of these tumors by the time they are recognized and treated. The advantages of preoperative chemotherapy and radiation remain unproved; however, several nonrandomized trials suggest a survival advantage in patients who show a complete response to preoperative adjuvant therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
